Market cap
$296,968 Mln
Revenue (TTM)
$55,635 Mln
P/E Ratio
23.6
P/B Ratio
7.3
Div. Yield
3 %
Key Ratios and Highlights
| Growth Score (%) | Quarterly | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | QoQ | YoY | 1-Year | 3-Years | 5-Years |
| Revenue | 6.61 | -2.82 | 0.81 | 6.04 | 1.53 |
| EBIT | 13.23 | -1.76 | 1.26 | 21.79 | 7.58 |
| Net Profit | 3.71 | -19.34 | -6.59 | 18.65 | 6.61 |
| EPS | 3.60 | -17.23 | -3.44 | 22.67 | 10.90 |
| Book Value | -- | -- | 8.80 | -4.67 | -0.73 |
| Key Ratios (%) | Average | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | 3-Years | 5-Years | TTM | Dec-25 | Dec-24 |
| EBIT-Margin
| 27.29 | 31.56 | 30.41 | 32.17 | 28.32 |
| Net Margin
| -- | -- | 22.93 | -- | -- |
| Return on equity
| 28.51 | 27.03 | 29.13 | 31.17 | 26.33 |
| Return on Capital
| 17.46 | 16.95 | -- | 17.74 | 16.10 |
| Return on Assets
| 12.79 | 12.43 | 8.80 | 12.91 | 11.81 |
| Debt to Equity (x)
| -- | -- | 0.90 | 0.80 | 0.71 |
Profitability
ROCE
--
--
Earning before interest and taxes / (Average net worth + Average total Debt) * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Novartis AG - ADR
|
--
|
17.74
|
16.10
|
18.53
|
7.48
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
ROE
29.13
Higher than Peers by 10.16
Profit after tax / Average Net worth * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Novartis AG - ADR
|
29.13
|
31.17
|
26.33
|
28.02
|
10.95
|
|
Peer Median
|
18.97
|
--
|
--
|
--
|
--
|
ROA
8.80
Higher than Peers by 5.95
Profit after tax / Average Total assets * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Novartis AG - ADR
|
8.80
|
12.91
|
11.81
|
13.66
|
5.58
|
|
Peer Median
|
2.86
|
--
|
--
|
--
|
--
|
EBIT Margin
30.41
Higher than Peers by 14.59
Operating profit (EBIT) / Net Sales * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Novartis AG - ADR
|
30.41
|
32.17
|
28.32
|
21.38
|
18.35
|
|
Peer Median
|
15.82
|
--
|
--
|
--
|
--
|
Net Margin
22.93
Higher than Peers by 14.70
Net profit / Total Income (Net sales plus other income) * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Novartis AG - ADR
|
22.93
|
25.64
|
23.09
|
31.83
|
16.00
|
|
Peer Median
|
8.23
|
--
|
--
|
--
|
--
|
Cash Profit Margin
--
--
(Net profit + Depreciation) / Gross Sales * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Novartis AG - ADR
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Revenue Growth
0.81
Lower than Peers by 7.24
Year on year growth in net sales
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Novartis AG - ADR
|
0.81
|
0.06
|
0.11
|
0.07
|
-0.01
|
|
Peer Median
|
8.05
|
--
|
--
|
--
|
--
|
EBIT Growth
1.26
Lower than Peers by 7.01
Year on year growth in operating profit (EBIT)
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Novartis AG - ADR
|
1.26
|
20.41
|
46.78
|
25.08
|
-68.49
|
|
Peer Median
|
8.26
|
--
|
--
|
--
|
--
|
Net Profit Growth
-6.59
Lower than Peers by 14.32
Year on year growth in profit after tax
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Novartis AG - ADR
|
-6.59
|
17.71
|
-19.59
|
113.52
|
-71.05
|
|
Peer Median
|
7.73
|
--
|
--
|
--
|
--
|
EPS Growth
-3.44
Lower than Peers by 13.83
Year on year growth in earnings per share
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Novartis AG - ADR
|
-3.44
|
0.22
|
-0.17
|
1.22
|
-0.70
|
|
Peer Median
|
10.39
|
--
|
--
|
--
|
--
|
Book Value Growth
1.32
Lower than Peers by 3.55
Year on year growth in book value per share
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Novartis AG - ADR
|
1.32
|
--
|
--
|
--
|
--
|
|
Peer Median
|
4.87
|
--
|
--
|
--
|
--
|
Solvency
Debt to Equity
0.90
Higher than Peers by 0.31
Total debt / Net worth
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Novartis AG - ADR
|
0.90
|
0.80
|
0.71
|
0.56
|
0.47
|
|
Peer Median
|
0.59
|
--
|
--
|
--
|
--
|
Short term debt to equity ratio
0.24
--
(Short term borrowings / Net worth)
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Novartis AG - ADR
|
0.24
|
0.13
|
0.19
|
0.14
|
0.10
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Current Ratio
0.86
Lower than Peers by 0.79
Current Assets / Current Liabilities and Provisions
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Novartis AG - ADR
|
0.86
|
1.12
|
1.04
|
1.16
|
1.29
|
|
Peer Median
|
1.65
|
--
|
--
|
--
|
--
|
Quick Ratio
0.67
Lower than Peers by 0.53
(Current Assets - Inventory) / Current Liabilities and Provisions
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Novartis AG - ADR
|
0.67
|
0.89
|
0.84
|
0.93
|
1.04
|
|
Peer Median
|
1.20
|
--
|
--
|
--
|
--
|
Interest Coverage
12.17
Higher than Peers by 7.40
Earning before interest and taxes (EBIT) / Interest Expenses
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Novartis AG - ADR
|
12.17
|
14.86
|
14.13
|
11.39
|
9.56
|
|
Peer Median
|
4.77
|
--
|
--
|
--
|
--
|
Operating Efficiency
Debtors to sales
17.71
Lower than Peers by 3.56
Debtors outstanding / Net Sales * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Novartis AG - ADR
|
17.71
|
19.95
|
15.88
|
20.09
|
22.77
|
|
Peer Median
|
21.27
|
--
|
--
|
--
|
--
|
Asset Turnover
0.38
Lower than Peers by 0.02
Sales / Average Total Assets
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Novartis AG - ADR
|
0.38
|
0.50
|
0.51
|
0.43
|
0.35
|
|
Peer Median
|
0.40
|
--
|
--
|
--
|
--
|
Receivable days
--
--
Average Debtors / Sales * 365
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Novartis AG - ADR
|
--
|
63.79
|
62.10
|
75.42
|
82.00
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Inventory Days
--
--
Average Inventory / Sales * 365
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Novartis AG - ADR
|
--
|
159.98
|
165.67
|
191.64
|
218.24
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Payable days
--
--
Average Creditors / Cost of goods sold * 365
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Novartis AG - ADR
|
--
|
120.44
|
135.23
|
147.48
|
168.70
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Cash Conversion Cycle
--
--
Receivable Days + Inventory Days - Payable Days
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Novartis AG - ADR
|
--
|
103.33
|
92.54
|
119.58
|
131.55
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Valuation
Price / Earnings
23.60
Lower than Peers by 13.72
Current share price divided by earning per share in the last twelve months
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Novartis AG - ADR
|
23.60
|
18.92
|
16.33
|
14.04
|
28.04
|
|
Peer Median
|
37.32
|
--
|
--
|
--
|
--
|
Price / Book Value
7.33
Lower than Peers by 0.42
Current share price divided by book value per share in the latest financial year
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Novartis AG - ADR
|
7.33
|
5.77
|
4.43
|
4.47
|
3.29
|
|
Peer Median
|
7.75
|
--
|
--
|
--
|
--
|
Dividend Yield
3.03
Higher than Peers by 2.53
Dividend per share in the past twelve months divided by current share price
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Novartis AG - ADR
|
3.03
|
--
|
--
|
--
|
--
|
|
Peer Median
|
0.50
|
--
|
--
|
--
|
--
|
EV/EBITDA
15.09
--
Enterprise Value (Current Market Capitalisation + Total Debt - Cash & Equivalents) / Earnings before interest, taxes, depreciation and taxes (EBITDA)
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Novartis AG - ADR
|
15.09
|
12.68
|
10.28
|
12.10
|
13.92
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Market Cap
296,968
Higher than Peers by 294,447
Current Share price multiplied by latest total number of shares outstanding
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Novartis AG - ADR
|
296,968
|
--
|
--
|
--
|
--
|
|
Peer Median
|
2,521
|
--
|
--
|
--
|
--
|